Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes.

Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA; MetGen Investigators; ACCORD/ACCORDion Investigators.

Diabetes. 2018 Jul;67(7):1428-1440. doi: 10.2337/db17-1164. Epub 2018 Apr 12.

PMID:
29650774
2.

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD.

Shah HS, Morieri ML, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2018 Feb;41(2):348-355. doi: 10.2337/dc17-1638. Epub 2017 Nov 28.

PMID:
29183908
3.

Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes.

Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA; ACCORD/ACCORDion Investigators.

Clin Pharmacol Ther. 2018 Apr;103(4):712-721. doi: 10.1002/cpt.798. Epub 2017 Nov 3.

PMID:
28736931
4.

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.

Yamanouchi M, Skupien J, Niewczas MA, Smiles AM, Doria A, Stanton RC, Galecki AT, Duffin KL, Pullen N, Breyer MD, Bonventre JV, Warram JH, Krolewski AS.

Kidney Int. 2017 Jul;92(1):258-266. doi: 10.1016/j.kint.2017.02.010. Epub 2017 Apr 7.

5.

Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation.

Shirakawa J, Fernandez M, Takatani T, El Ouaamari A, Jungtrakoon P, Okawa ER, Zhang W, Yi P, Doria A, Kulkarni RN.

Cell Metab. 2017 Apr 4;25(4):868-882.e5. doi: 10.1016/j.cmet.2017.02.004. Epub 2017 Mar 9.

6.

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

Morieri ML, Shah H, Doria A; the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Genetic Study Group.

N Engl J Med. 2016 Dec 8;375(23):2304-2305. doi: 10.1056/NEJMc1607380. No abstract available.

PMID:
28112899
7.

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.

Shah HS, Gao H, Morieri ML, Skupien J, Marvel S, Paré G, Mannino GC, Buranasupkajorn P, Mendonca C, Hastings T, Marcovina SM, Sigal RJ, Gerstein HC, Wagner MJ, Motsinger-Reif AA, Buse JB, Kraft P, Mychaleckyj JC, Doria A.

Diabetes Care. 2016 Nov;39(11):1915-1924. Epub 2016 Aug 15.

8.

SerpinB1 Promotes Pancreatic β Cell Proliferation.

El Ouaamari A, Dirice E, Gedeon N, Hu J, Zhou JY, Shirakawa J, Hou L, Goodman J, Karampelias C, Qiang G, Boucher J, Martinez R, Gritsenko MA, De Jesus DF, Kahraman S, Bhatt S, Smith RD, Beer HD, Jungtrakoon P, Gong Y, Goldfine AB, Liew CW, Doria A, Andersson O, Qian WJ, Remold-O'Donnell E, Kulkarni RN.

Cell Metab. 2016 Jan 12;23(1):194-205. doi: 10.1016/j.cmet.2015.12.001. Epub 2015 Dec 15.

9.

Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools.

Teo AK, Gupta MK, Doria A, Kulkarni RN.

Mol Metab. 2015 Jun 20;4(9):593-604. doi: 10.1016/j.molmet.2015.06.006. eCollection 2015 Sep. Review.

10.

CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease.

Bassi R, Fornoni A, Doria A, Fiorina P.

Diabetologia. 2016 Jan;59(1):21-9. doi: 10.1007/s00125-015-3766-6. Epub 2015 Sep 26. Review.

11.

Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes.

Prudente S, Bailetti D, Mendonca C, Mannino GC, Fontana A, Andreozzi F, Hastings T, Mercuri L, Alberico F, Basile G, Copetti M, Sesti G, Doria A, Trischitta V.

Atherosclerosis. 2015 Sep;242(1):334-9. doi: 10.1016/j.atherosclerosis.2015.07.030. Epub 2015 Jul 17.

12.

Loss-of-Function Mutations in APPL1 in Familial Diabetes Mellitus.

Prudente S, Jungtrakoon P, Marucci A, Ludovico O, Buranasupkajorn P, Mazza T, Hastings T, Milano T, Morini E, Mercuri L, Bailetti D, Mendonca C, Alberico F, Basile G, Romani M, Miccinilli E, Pizzuti A, Carella M, Barbetti F, Pascarella S, Marchetti P, Trischitta V, Di Paola R, Doria A.

Am J Hum Genet. 2015 Jul 2;97(1):177-85. doi: 10.1016/j.ajhg.2015.05.011. Epub 2015 Jun 11.

13.

Serum resistin and glomerular filtration rate in patients with type 2 diabetes.

Moreno LO, Salvemini L, Mendonca C, Copetti M, De Bonis C, De Cosmo S, Doria A, Trischitta V, Menzaghi C.

PLoS One. 2015 Mar 26;10(3):e0119529. doi: 10.1371/journal.pone.0119529. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127250.

14.

Genetic Variant at the GLUL Locus Predicts All-Cause Mortality in Patients With Type 2 Diabetes.

Prudente S, Shah H, Bailetti D, Pezzolesi M, Buranasupkajorn P, Mercuri L, Mendonca C, De Cosmo S, Niewczas M, Trischitta V, Doria A.

Diabetes. 2015 Jul;64(7):2658-63. doi: 10.2337/db14-1653. Epub 2015 Feb 12.

15.

Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.

Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elía E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM.

Cell Metab. 2015 Jan 6;21(1):33-8. doi: 10.1016/j.cmet.2014.12.009.

16.

Joint effect of insulin signaling genes on all-cause mortality.

Menzaghi C, Fontana A, Copetti M, Rizza S, Spoto B, Buranasupkajorn P, Tripepi G, Marucci A, Bailetti D, Hastings T, Testa A, Mendonca C, Mallamaci F, De Cosmo S, Bacci S, Federici M, Doria A, Zoccali C, Trischitta V.

Atherosclerosis. 2014 Dec;237(2):639-44. doi: 10.1016/j.atherosclerosis.2014.10.005. Epub 2014 Oct 24.

17.

Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes.

Qi L, Qi Q, Prudente S, Mendonca C, Andreozzi F, di Pietro N, Sturma M, Novelli V, Mannino GC, Formoso G, Gervino EV, Hauser TH, Muehlschlegel JD, Niewczas MA, Krolewski AS, Biolo G, Pandolfi A, Rimm E, Sesti G, Trischitta V, Hu F, Doria A.

JAMA. 2013 Aug 28;310(8):821-8. doi: 10.1001/jama.2013.276305.

18.

Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH.

Diabetes Care. 2014;37(1):226-34. doi: 10.2337/dc13-0985. Epub 2013 Aug 12.

19.

Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance.

Liew CW, Boucher J, Cheong JK, Vernochet C, Koh HJ, Mallol C, Townsend K, Langin D, Kawamori D, Hu J, Tseng YH, Hellerstein MK, Farmer SR, Goodyear L, Doria A, Blüher M, Hsu SI, Kulkarni RN.

Nat Med. 2013 Feb;19(2):217-26. doi: 10.1038/nm.3056. Epub 2013 Jan 6.

20.

Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Doria A, Niewczas MA, Fiorina P.

Semin Nephrol. 2012 Sep;32(5):437-44. doi: 10.1016/j.semnephrol.2012.07.006.

Supplemental Content

Loading ...
Support Center